Skip to content

Absci Corporation ABSI Cash & Equivalents

Cash & Equivalents at other companies

Schrodinger logo
SchrodingerSDGR
$267.72M-20.7%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$665.18M+30.6%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
$97.19M+100%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$102.06M-44.6%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$248.47M+152%
ADMA Biologics logo
ADMA BiologicsADMA
$138.15M+92.9%

Other financials

Income statement

See full
Revenue$215.0K-81.8%
Operating income-$30.8M-11.2%
Net income-$29.6M-12.3%
EPS (diluted)-$0.19+9.5%

Balance sheet

See full
Total debt$4.0M-37.2%
Total equity$172.0M-13.5%
Total assets$195.6M-15.9%

Cash flow

See full
Operating cash flow-$26.3M-20.5%
CapEx$30.0K+20.0%
Free cash flow-$26.3M-20.5%

Valuation

See full
Market cap$1.57B+341%
Enterprise value$1.57B+425%
P/S855.5×+782×

Profitability

See full
Operating margin-6,723%-14,525pp
Net margin-6,450.8%-13,699pp
FCF margin-5,365.2%-9,300pp

Returns & leverage

See full
Return on equity-63.9%+28.0pp
Debt / equity0.0×
Current ratio6.6×+0.9×

Where this comes from

Reported directly by Absci Corporation in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Absci Corporation’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Absci Corporation's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Absci Corporation's cash & equivalents?
Absci Corporation (ABSI) reported cash & equivalents of $9.69M in Q1 2026.
How has Absci Corporation's cash & equivalents changed year-over-year?
Absci Corporation's cash & equivalents decreased by 84.9% year-over-year, from $64.13M to $9.69M.
What is the long-term trend for Absci Corporation's cash & equivalents?
Over 5 years (2020 to 2025), Absci Corporation's cash & equivalents has grown at a -21.7% compound annual growth rate (CAGR), from $71.71M to $21.08M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.